GeoVax Labs Inc.
1256 Briarcliff Road
Atlanta
Georgia
30306
United States
Tel: 404-727-0971
Fax: 404-712-9357
Website: http://www.geovax.com/
266 articles with GeoVax Labs Inc.
-
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
3/15/2023
GeoVax Labs, Inc. congratulates its colleague and collaborator, Don Diamond, Ph.D. for recognition as a finalist for the Best Academic/Research Team Award, part of the Vaccine Industry Excellence Awards to be held during the World Vaccine Congress in Washington, DC on April 3-6, 2023.
-
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
2/15/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), and EmVenio Research today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 clinical trial evaluating GEO-CM04S1 as a COVID-19 booster vaccine in healthy patients.
-
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
2/7/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centers -- Stanford University, Emory University and Thomas Jefferson University.
-
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
1/4/2023
GeoVax Labs, Inc. announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.
-
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
10/26/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.
-
GeoVax to Present at Upcoming October 2022 Investor Conferences
10/6/2022
GeoVax Labs, Inc. announced that its Chairman & CEO, David Dodd, will present at the Midcap Rodeo: Windy City Roundup 2022 in Chicago, IL and at the LD Micro Main Event XV in Los Angeles, CA.
-
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 2:30 p.m. Eastern Standard Time.
-
GeoVax Announces Addition to Its Board of Directors
9/1/2022
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced that it has appointed Nicole Lemerond, CFA, to its Board of Directors.
-
After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.
-
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
7/26/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report second quarter 2022 financial results on Wednesday, August 3, 2022 after the market closes.
-
Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.
-
This week's Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.
-
GeoVax Announces Upcoming Presentations at Scientific Conferences - May 04, 2022
5/4/2022
GeoVax Labs, Inc. announced that it will be represented during presentations at the following upcoming scientific conferences.
-
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.
-
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
3/14/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s two ongoing Phase 2 clinical trials of its vaccine candidate, GEO-CM04S1, against SARS-CoV-2.
-
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows It Produced Robust Antibodies and T Cells Against SARS-CoV-2
3/10/2022
A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a Phase 1 clinical trial led by John Zaia, M.D., Aaron D. Miller and Edith Miller Chair for Gene Therapy, according to a study published in The Lancet Microbe.
-
BioSpace Movers & Shakers, Aug. 28
8/28/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-CoV-2 (COVID-19) Vaccine Development
5/1/2020
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.
-
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
3/18/2020
GeoVax Labs, Inc. provided an update on its development of a vaccine for prevention/control of novel coronavirus disease caused by SARS-Cov-2 coronavirus.
-
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
3/4/2020
GeoVax Labs, Inc. provided an update on its development of a vaccine for prevention/control of novel coronavirus disease caused by SARS-Cov-2 coronavirus.